论文部分内容阅读
目的:探讨芪苈强心胶囊对急性心肌梗死患者的治疗价值。方法:将2016年2月至2017年3月开封市第二人民医院76例急性心肌梗死患者作为研究对象根据方法分组,各38例。常规组采用常规治疗,芪苈强心组在常规组基础上采用芪苈强心胶囊。比较两组急性心肌梗死治疗效果;不良反应发生率;干预前后患者心功能分级、N-末端B型利钠肽原、左心射血分数。结果:芪苈强心组急性心肌梗死治疗效果高于常规组,差异具有统计学意义(P<0.05);芪苈强心组不良反应发生率和常规组比较,差异均无统计学意义(P>0.05);干预前两组心功能分级、N-末端B型利钠肽原、左心射血分数相近,差异均无统计学意义(P>0.05);干预后芪苈强心组心功能分级、N-末端B型利钠肽原、左心射血分数优于常规组,差异具有统计学意义(P<0.05)。结论:芪苈强心胶囊对急性心肌梗死患者的治疗价值确切,可改善患者心功能,安全有效,无明显不良反应。
Objective: To investigate the therapeutic value of Qili Qiangxin Capsule in patients with acute myocardial infarction. Methods: From February 2016 to March 2017, 76 patients with acute myocardial infarction in the Second People’s Hospital of Kaifeng City were enrolled in this study according to the method and 38 patients in each group. Routine treatment was given in the conventional group. Qili Qiangxin treatment group was given Qi Qiang Qiangxin capsule on the basis of conventional group. The therapeutic effect of acute myocardial infarction was compared between two groups; the incidence of adverse reactions; before and after intervention in patients with cardiac function classification, N-terminal B-type natriuretic peptide, left ventricular ejection fraction. Results: The therapeutic effect of Qiliqiangxin group on acute myocardial infarction was higher than that of the conventional group (P <0.05). The incidence of adverse reactions in Qiliqiangxin group was not significantly different from that of the conventional group (P > 0.05). There was no significant difference in cardiac function between the two groups before intervention, N-terminal B-type natriuretic peptide and left ventricular ejection fraction (P> 0.05) Grading, N-terminal B-type natriuretic peptide, left ventricular ejection fraction better than the conventional group, the difference was statistically significant (P <0.05). Conclusion: Qili Qiangxin Capsule has definite therapeutic value for patients with acute myocardial infarction, which can improve the cardiac function, be safe and effective, and have no obvious adverse reactions.